spacer
home > ebr > autumn 2003 > upping the anti - keeping ahead of antibiotic resistance
PUBLICATIONS
European Biopharmaceutical Review

Upping the Anti - Keeping Ahead of Antibiotic Resistance

The prevalence of antibacterial resistance seems to be rising, yet few new antibiotics have been approved in recent years. How dire is the situation and what is Enanta doing to address it?

Drug resistance is continually increasing and the supply of new antibiotics has slowed. Resistance to antibiotics varies by geographic region and there is no doubt that clinically important species of bacteria such as Streptococci, one of the major causes of respiratory tract infections, have developed resistance to more than one antibiotic. A recent study completed by the Centers for Disease Control in the US concluded that by next year 40 per cent of Streptococci will be resistant to both penicillins and macrolides.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Aimee Dingwell, News Editor at BioCentury Publications Inc, talks to Spiros Jamas, President and CEO of Enanta

Dr Spiros Jamas graduated from the University of Manchester Institute of Science and Technology, England, in 1981 with a BSc (Hons) in Chemical Engineering. He also holds a MSc in Food Science and Technology and a PhD in Biotechnology from the Massachusetts Institute of Technology.

In 1988, Dr Jamas founded and served as President, CEO and Director of Alpha-Beta Technology, a company that developed medical applications of carbohydrates. During his tenure at Alpha-Beta, he was instrumental in raising $200 million through venture capital, as well as public financings. Dr Jamas has also directed two INDs, five Phase I, three Phase II, and two Phase III clinical trials, while concurrently acquiring another privately held biotechnology company. Following this, he held the position of President and CEO of Repair Inc, a biopharmaceutical company that developed sustained-release angiogenesis therapies for the repair of diseased organs and tissues.

Dr Jamas has served as President and CEO of Enanta since the company's inception in 1999, providing scientific and business leadership.

spacer
Aimee Dingwell
spacer
spacer
spacer
Dr Spiros Jamas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Harlan and Fluofarma Sign Strategic Collaboration Agreement

Itingen, Switzerland; July 15, 2014 — Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a contract research organization specializing in high content analysis, have announced a strategic partnership that will strengthen the companies’ drug discovery and translational medicine services.
More info >>

White Papers

The Process of Informed Consent (written by ACRP)

CenterWatch

Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >>

 
Industry Events

Drug Delivery Partnerships

17-18 September 2014, Radisson Blu Hotel, Berlin, Germany

Drug Delivery Partnerships EUROPE is the leading industry drug delivery conference bringing you valuable insights into the latest approaches, formulations, technologies and systems to optimise your product portfolios.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement